PARP Inhibitors Advance in Ovarian Cancer (Dr. Birrer) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, November 16, 2016

PARP Inhibitors Advance in Ovarian Cancer (Dr. Birrer)



PARP Inhibitors Advance in Ovarian Cancer


With olaparib approved and niraparib and rucaparib advancing through clinical development, PARP inhibition is becoming a valuable option in the ovarian cancer armamentarium.

In a discussion at the 2016 CFS, Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, said he anticipates that the FDA will approve niraparib and rucaparib in ovarian cancer in the next 6 months to a year.

The focus now, according to Birrer, is on optimizing the use of these treatments. “We need to find the best patient population to treat and we need to define whether we use these drugs in maintenance treatment, or early or late [in sequencing].” - See more at: http://www.targetedonc.com/conference/cfs-2016/parp-inhibitors-advance-in-ovarian-cancer#sthash.FQHTlMVQ.dpuf
With olaparib approved and niraparib and rucaparib advancing through clinical development, PARP inhibition is becoming a valuable option in the ovarian cancer armamentarium.

In a discussion at the 2016 CFS, Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, said he anticipates that the FDA will approve niraparib and rucaparib in ovarian cancer in the next 6 months to a year.

The focus now, according to Birrer, is on optimizing the use of these treatments. “We need to find the best patient population to treat and we need to define whether we use these drugs in maintenance treatment, or early or late [in sequencing].” - See more at: http://www.targetedonc.com/conference/cfs-2016/parp-inhibitors-advance-in-ovarian-cancer#sthash.FQHTlMVQ.dpuf

0 comments :

Post a Comment

Your comments?